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3-month, estimated, direct cost savings for treatment with GEn ranged from $94.40 
to $202.80. Similarly, the per-patient indirect cost savings due to improved work 
productivity ranged from $1447.30 to $2587.60. Thus, total 3-month cost savings 
ranged from $1541.70 to $2790.40. CONCLUSIONS: Based on these ﬁndings, the 
estimated annual total treatment cost savings with GEn is approximately $6,000 to 
$11,000 per patient.
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OBJECTIVES: To evaluate the effects on direct and indirect costs of initiating prega-
balin or duloxetine in employees diagnosed with painful diabetic peripheral neuropa-
thy (pDPN). METHODS: Employees (18–64 years old) with a diagnosis of DPN and 
at least one claim for a pDPN-related pain medication were identiﬁed using the 
Thomson Reuters MarketScan® Commercial Claims and Encounters Research Data-
base (2005–2008). Patients were continuously enrolled in the 6-month pre- and 
6-month post-initiation periods. To control for selection bias, propensity scored 
matched pregabalin and duloxetine new starts were evaluated. Key study outcomes 
including imputed medically-related work loss, prescription and health care utiliza-
tion, and associated expenditures were analyzed using bivariate statistics and multi-
variate models in a difference-in-difference approach. RESULTS: A total of 946 
employees with pDPN (473 per group) were identiﬁed. In the pre-index period, there 
were no statistically signiﬁcant differences between groups in age (mean 54.0 ± 5.6 
pregabalin and 53.3 ± 7.5 duloxetine), gender (females 52% pregabalin, 48% dulox-
etine), geographic distribution, insurance plan types, comorbidities, medication use, 
health care resource utilization or health care expenditures. The average number of 
prescriptions in the 6-month post-index period was 2.9 ± 1.9 for pregabalin and 3.1 
± 2.1 for duloxetine. There were no signiﬁcant differences between treatment groups 
for pre-to-post changes in opioid utilization (marginal effect 1.3 percentage points 
fewer pregabalin opioid patients, p = 0.328) as well as the number of pDPN-related 
pain medications (marginal effect 0.108 more medications for pregabalin, p = 0.506). 
The adjusted marginal effects for pre-to-post changes in all-cause health care expen-
ditures ($154 greater increase for pregabalin patients, p = 0.895), pDPN-attributable 
expenditures ($145 greater increase for pregabalin patients, p = 0.359) and indirect 
costs ($458 relative decrease for pregabalin patients, p = 0.324) were not statistically 
signiﬁcant. CONCLUSIONS: There were no signiﬁcant pre-to-post differences 
between pregabalin and duloxetine treatment groups in opioid use, DPN-related pain 
medication use, pDPN-attributable, all-cause and indirect expenditures.
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OBJECTIVES: To estimate the differences in costs of treating migraine headaches 
employing a stratiﬁed care (STRAT) approach versus the more common stepped care 
(STEP) using MIDAS scores in the U.S. STRAT using MIDAS scores has been shown 
to be cost-effective in other settings. However, STRAT is not widely used in the U.S. 
In this study, a published decision model was adapted to the U.S. setting and the 
differences in costs were evaluated for STEP and STRAT in the U.S. by differentiating 
the patients by MIDAS scores. METHODS: Published values for costs of physician/
specialist visits, over the counter (OTC) analgesics, aspirin+metoclopramide (AM), 
triptans, and hospitalizations were used to create a microsimulation model for a U.S. 
perspective. Therapy effectiveness for OTCs, AM, and triptans by MIDAS scores I, 
II, and III were taken from the published decision tree. In the base-case the proportion 
of MIDAS I, II, and III patients were 5%, 25%, and 70% respectively. STEP patients 
were forced through each phase of therapy regardless of MIDAS score. STRAT 
patients were moved ahead to advanced phases of therapy given higher MIDAS score. 
In the model, a sample of 1000 patients is taken and is distributed according to the 
MIDAS scores. The costs are attached to each node of the treatment algorithm to 
obtain the total costs. RESULTS: Base case results showed that mean annual direct 
medical costs on STEP for the population were $1229 compared to $1088 for STRAT. 
Sensitivity analysis showed that the differences in costs (STEP-STRAT) were $210 for 
a cohort of MIDAS II patients and $142 for a cohort of MIDAS III patients. CON-
CLUSIONS: Model results indicate that STRAT has the potential for cost savings in 
a U.S. setting. Increased awareness and used of STRAT can beneﬁt patients, providers, 
and payers in the treatment of migraine headache.
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OBJECTIVES: To determine if the pharmacy provider model for patients with relaps-
ing remitting multiple sclerosis (MS) on biologic disease modifying drugs (DMD) 
impacts medical costs. METHODS: A retrospective cohort study design was used. 
Pharmacy and medical claims data for MS patients (N = 5,232) were extracted for 
2008 from a pharmacy beneﬁt management (PBM) company. The two study popula-
tions included: 1) patients who received therapy from a specialty pharmacy, and 2) 
those who received therapy from retail pharmacies. Adherence was measured using a 
Medication Possession Ratio (MPR), with patients considered adherent for MPR ≥ 
80%. Nonparametric statistical tests and multivariate log-linear regression analyses 
were used to determine differences between the two populations. RESULTS: The 
results suggest that MS patients receiving therapy from a specialty pharmacy have 
signiﬁcantly lower total medical costs than patients who receive therapy from a retail 
pharmacy [−0.18; 95% CI −0.33, −0.02]. Overall, specialty pharmacy MS patients 
tended to have lower total medical costs, IP costs and ofﬁce visits as compared to 
retail patients. CONCLUSIONS: DMD therapy is considered an effective treatment 
for relapsing-remitting MS patients. Specialty pharmacies often have additional patient 
care services that help the patient manage their therapy more effectively. This study 
demonstrates that MS patients taking a DMD who are medically managed in a spe-
cialty pharmacy setting can achieve lower medical costs. This has signiﬁcant implica-
tions for insurers and patients.
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OBJECTIVES: To present a methodology for matching Alzheimer’s disease (AD) 
patients and their spouses to non-AD couples using an administrative claims database 
to assess caregiver burden. METHODS: Data were extracted from MarketScan claims 
databases from January 1, 2002--December 31, 2008. Patients with an AD ICD-9 
diagnosis code and with a spouse in the database were eligible for matching; their 
index date was the date of ﬁrst AD diagnosis. Couples with no AD diagnoses were 
eligible as controls and were matched 1:1 to AD couples based on patient and spouse 
birth years ± 3 years, index date ± 1 year (deﬁned as eligibility midpoint), gender, and 
CDPS risk adjuster score prior to index date. All subjects had continuous eligibility 
12+ months pre- and post-index date. RESULTS: Of 12,476 AD patients with spouses 
who met all inclusion criteria, 12,370 matched to a control couple. AD couples who 
did not match often had a greater age difference than available control couples. More 
AD patients and spouses utilized AD medications, antidepressants, anxiolytics, and 
antipsychotics pre-index date than their controls (p < 0.05). AD patients had a higher 
pre-index prevalence of non-AD dementia, anxiety, and psychosis than control 
patients (p < 0.001). AD spouses had increased antidepressant use post index 
(p < 0.001); control spouses showed no change. AD patients had a greater increase in 
total costs post index date than control patients (p < 0.001); no difference in total 
cost was observed between AD and control spouses, whose increases were similar to 
control patients. CONCLUSIONS: Matching on a risk adjuster score resulted in 
similar rates of chronic conditions between case and control couples but may have 
limited the ability to detect whether AD impacts spouse health care resource use. 
However, signiﬁcant differences in prevalence of dementia and other mental health 
conditions were noted for AD patients, and an increase in antidepressant use suggests 
such a trend.
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OBJECTIVES: To measure health care costs related to epilepsy severity using real-life 
claims data (Pharmetrics®, IMS, USA) in a representative sample from a U.S. commer-
cially-insured population. METHODS: The observation period ranged from January 
2006-December 2007. Patients with at least two diagnoses of epilepsy before the 
observation period and at least two claims for anti-epileptic drugs (AEDs) during the 
observation period were included. As Pharmetrics® does not report data on disease 
severity, the number of epilepsy-related emergency room visits over two years (0, 1, 2, 
≥3) was used as a proxy. Covariates included age, gender, region, epilepsy-type, number 
of co-morbidities, concomitant AEDs, and treatment duration. Annualized costs were 
split into AED medications and non-AED costs. Non-AED costs included non-AED 
medications and ‘other’ costs including emergency room visits, hospitalizations, and 
physician visits. RESULTS: A total fo 9163 patients were included, with 14% in the 
most severe category (≥3 ER visits). Total annualized costs ranged from US$6,000 to 
$33,000 depending on disease severity. AED costs were not linked to severity; however 
‘other costs’ increased disproportionately with disease severity. In the unadjusted 
analysis, mean annualized AED, non-AED medication and ‘other’ costs were $2,513, 
$1,276 and $2,522, respectively, for those with no ER visits and $3,279, $3,457 and 
$26,270, respectively, for those with ≥3 ER visits. The rise in ‘other’ costs with severity 
was mainly attributable to hospitalization costs. In the adjusted analysis, the difference 
between AED and ‘other’ costs increased signiﬁcantly with epilepsy severity, number 
of co-morbidities, and age, whereas it decreased with improved AED compliance. 
CONCLUSIONS: Non-AED treatment costs increased disproportionately with epi-
lepsy severity, driven mainly by hospitalization. AED medication costs were not related 
to disease severity. This analysis suggests cost savings may be achieved through targeted 
strategies and improvement of patient compliance in cases of severe epilepsy.
